NCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT03789110 2026-02-06
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02393794 2025-10-06
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03414684 2025-09-29
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03650894 2025-03-10
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Providence Health & Services
Phase 2 Active not recruiting